CLL Extended 1: FCM CLL Panel and Karyotyping and FISH For 17p

Chromosomal analysis helps to understand the genetic characteristics of CLL cells, which can affect how the disease progresses and responds to treatment. It's important for risk stratification and for making informed treatment decisions.

Based on the results of this test, your doctor will have more information about the nature of your CLL. This can help in selecting a treatment that is more likely to be effective based on your CLL’s genetic makeup.

No special preparation is needed for this test. However, it is advisable to tell your doctor about any medications you are currently taking.

In a healthy individual, the 17p deletion and other chromosomal abnormalities would not be present. Detecting these abnormalities in someone with CLL provides important information about the disease.

Consult a hematologist or oncologist who has experience in treating blood cancers.

This test is usually done at the time of diagnosis. It might be repeated if there's a significant change in the disease or if your doctor needs more information for treatment decisions.

No, the chromosomal abnormalities detected by this test are genetic and not influenced by lifestyle.

CLL can be managed through regular monitoring and following the treatment plan outlined by your doctor. Engaging in a healthy lifestyle and staying informed about your condition can also be beneficial.

If chromosomal abnormalities are detected, it means that the CLL may be more aggressive or resistant to certain treatments. Your doctor will discuss the results with you and adjust the treatment plan as needed.

Yes, it’s possible for the 17p deletion to occur as CLL progresses. This is why it is sometimes necessary to repeat testing at different stages of the disease.

Your doctor might also recommend other blood tests, imaging studies, and bone marrow biopsy to fully evaluate the state of your CLL.

While CLL is generally not considered curable, many treatments can effectively manage the disease for years. Also, new treatments are constantly being researched.

Patients with the 17p deletion often have a more aggressive form of CLL. However, prognosis can vary widely and newer targeted therapies have shown effectiveness in treating this subset of CLL.

Understanding the genetic composition of your CLL cells is crucial in managing the disease effectively. The CLL Extended 1 test provides your doctor with valuable information on the characteristics of the CLL cells, including the presence of the 17p deletion which is known to be associated with a high-risk form of the disease. This information is instrumental in devising a personalized treatment plan. Regular monitoring and adherence to the treatment plan are vital in managing CLL.